Perioperative Regimen Of Neoadjuvant Opdivo And Chemotherapy Followed By Adjuvant Opdivo Shows Improvement In Event-Free Survival For Patients With Resectable Non-Small Cell Lung Cancer In Phase 3 Checkmate -77T Trial
Portfolio Pulse from Benzinga Newsdesk
The Phase 3 Checkmate -77T trial of Neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo showed a 42% reduction in the risk of disease recurrence, progression or death in patients with resectable non-small cell lung cancer. The data from the trial will be presented at the European Society for Medical Oncology Congress 2023.
October 17, 2023 | 7:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol-Myers Squibb's Neoadjuvant Opdivo has shown promising results in a Phase 3 trial, potentially boosting the company's position in the cancer treatment market.
The positive results from the Phase 3 trial of Neoadjuvant Opdivo could potentially lead to regulatory approval and increased sales for Bristol-Myers Squibb. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100